
Sign up to save your podcasts
Or


Do you know how to apply best practices for HER2 testing and identify patients who may benefit from targeted therapies? Join us to learn more!
Credit available for this activity expires: 4/28/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g?ecd=bdc_podcast_libsyn_mscpedu
Explore how rapid-acting therapies transform major depressive disorder (MDD) care--uncover the neurobiology and mechanisms driving faster antidepressant effects.
Credit available for this activity expires: [04/27/27] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/mechanisms-behind-rapid-acting-treatments-major-depressive-2026a1000cld?ecd=bdc_podcast_libsyn_mscpedu
How do you turn your patients' calcium scores into clear, personalized prevention plans?
Credit available for this activity expires: 4/28/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/episode-two-cracking-code-coronary-artery-calcium-cac-2026a1000clt?ecd=bdc_podcast_libsyn_mscpedu
Master assessing high-risk hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC): outsmart recurrence with data-driven precision.
Credit available for this activity expires: 04/27/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/cracking-code-optimizing-outcomes-all-patients-high-risk-hr-2026a1000crj?ecd=bdc_podcast_libsyn_mscpedu
Do you know when to advance patients with IBS-C from over-the-counter to prescription treatments?
Credit available for this activity expires: 04/22/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/breaking-otc-cycle-optimizing-prescription-therapy-ibs-c-2026a1000bpz?ecd=bdc_podcast_libsyn_mscpedu
Are you confident in identifying the risk for recurrence in early-stage HR-positive, HER2-negative breast cancer? Credit available for this activity expires: [04/21/27] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?ecd=bdc_podcast_libsyn_mscpedu
Risk vs Biology: Which carries more weight in the decision to escalate therapy?
Credit available for this activity expires: 04/21/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd?ecd=bdc_podcast_libsyn_mscpedu
Are you up to date on the latest clinical developments for steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved ejection fraction (HFpEF)?
Credit available for this activity expires: 04/08/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/beyond-headlines-critical-look-mra-evidence-hfpef-2026a1000al7?ecd=bdc_podcast_libsyn_mscpedu
Did you know that antibody-drug conjugates (ADCs) targeting Trop2 have demonstrated significant clinical potential for patients with TNBC?
Credit available for this activity expires: 4/8/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/front-antibody-drug-conjugates-shifting-paradigm-metastatic-2026a1000a9z?ecd=bdc_podcast_libsyn_mscpedu
Your patient asks, "Will switching to a biosimilar make my disease worse?" Learn how to confidently address their concerns.
Credit available for this activity expires: 4/7/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003282?ecd=bdc_podcast_libsyn_mscpedu
From the publisher's feed

136 Listeners

697 Listeners

496 Listeners

162 Listeners

103 Listeners

892 Listeners

13 Listeners

16 Listeners

290 Listeners

265 Listeners

3,343 Listeners

1,157 Listeners

195 Listeners

93 Listeners

520 Listeners

372 Listeners

170 Listeners

60 Listeners

8 Listeners

431 Listeners